Home

Albert Cha

CIK 1397906 · last filed 2023-09-28

Albert Cha is a corporate insider who has filed 32 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for ASND, was dated Mar 2, 2026. Across all open-market trades the lifetime net is +$41.7M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $50.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$50.56M

Companies

7

Total Filings

32

Lifetime Open-Market Net

$41.68M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KalVista Pharmaceuticals, Inc. (KALV) Delisted Director 1,144,179 $27.00 $30.89M $21.85M 13 2023-09-28
BHVN Director 2,049,545 $13.77 $28.22M $7.99M 3 2018-05-03
VYNE Therapeutics Inc. (MNLO) Delisted Director 2,606,982 — — $5.00M 1 2018-01-29
ACRS Director 4,191,397 $5.33 $22.34M $5.15M 3 2016-07-01
Sierra Oncology, Inc. (DNAI) Delisted Director 2,064,308 — — $3.74M 1 2015-07-21
ALBIREO PHARMA, INC. (BIOD) Delisted Director 51,799 — — -$2.05M 3 2008-03-04
BIOFORM MEDICAL INC (BFRM) Delisted Director 87,410 — — $0 1 2007-11-14

Recent Filings

32 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-03-02 ASND Notice (144) −2,100 -$508.4K EDGAR
2025-03-04 ASND Notice (144) −1,470 -$223.6K EDGAR
2024-03-05 ASND Notice (144) −658 -$98.7K EDGAR
2023-09-28 KalVista Pharmaceuticals, Inc. (KALV) Delisted Grant (A) — $0 EDGAR
2023-09-13 KalVista Pharmaceuticals, Inc. (KALV) Delisted Mixed — -$54.2K EDGAR
2023-09-11 KalVista Pharmaceuticals, Inc. (KALV) Delisted Notice (144) −18,000 -$180.0K EDGAR
2023-09-07 ASND Notice (144) −77,458 -$8.05M EDGAR
2022-10-17 KalVista Pharmaceuticals, Inc. (KALV) Delisted Grant (A) — $0 EDGAR
2021-10-01 KalVista Pharmaceuticals, Inc. (KALV) Delisted Grant (A) — $0 EDGAR
2020-11-03 KalVista Pharmaceuticals, Inc. (KALV) Delisted Buy (P) +115,686 $1.99M EDGAR
Showing 1–10 of 32
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.